ZyVersa Therapeutics' CEO, Stephen C. Glover to Participate in a Panel Discussion Titled “Inflammation Illuminated,”at Benzinga’s Virtual Healthcare Summit 2024 on March 20, 2024
March 14, 2024 07:57 ET
|
ZyVersa Therapeutics
Mr. Glover will talk about inflammasomes, and how they trigger development and spread of damaging inflammation, the culprit behind many deadly diseases.
Allyx Therapeutics Announces Positive Phase 1b Multiple Ascending Dose Data and Advances ALX-001 to Patients
March 11, 2024 08:05 ET
|
Allyx Therapeutics Inc.
Allyx Therapeutics Announces Positive Phase 1b Multiple Ascending Dose Data and Advances ALX-001 to Patients
NodThera’s NLRP3 Inhibitor NT-0796 Reverses Neuroinflammation in Parkinson’s Disease Phase Ib/IIa Trial
March 07, 2024 07:00 ET
|
NodThera
NodThera Ltd (“NodThera” or the “Company”) NodThera’s NLRP3 Inhibitor NT-0796 Reverses Neuroinflammation in Parkinson’s Disease Phase Ib/IIa Trial Brain-penetrant NLRP3 inflammasome inhibitor...
Parkinson’s Disease Patient Identification and Education Will Need to Improve When New Disease Modifying Therapies Are Approved, According to Spherix Global Insights
February 16, 2024 10:40 ET
|
Spherix Global Insights
EXTON, PA, Feb. 16, 2024 (GLOBE NEWSWIRE) -- Millions of people worldwide are affected by Parkinson’s disease (PD), prompting the need for effective disease-modifying therapies (DMTs) to target this...
ZyVersa Therapeutics Highlights Review Article Substantiating That Inflammasome Activation Is Pathogenic in Multiple Neurological Diseases
February 14, 2024 07:53 ET
|
ZyVersa Therapeutics
Inflammation resulting from activation of more than one type inflammasome and ASC specks contribute to development and progression of neurological disease
Durin Technologies Receives Additional Funding to Accelerate Growth
December 05, 2023 10:00 ET
|
Durin Technologies
Stratford, NJ, Dec. 05, 2023 (GLOBE NEWSWIRE) -- Durin Technologies, Inc., an innovator in neurodegenerative disease diagnostic test development and commercialization, today announced funding of...
Alterity Therapeutics to Host Webcast to Discuss ATH434 Efficacy Data in Primates and Recent Clinical Progress
December 04, 2023 16:35 ET
|
ALTERITY THERAPEUTICS LIMITED
MELBOURNE, Australia and SAN FRANCISCO, Dec. 04, 2023 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to...
Gain Therapeutics to Participate in FORCE Family Office Event with Zacks Small-Cap Research
December 04, 2023 08:00 ET
|
Gain Therapeutics, Inc.
BETHESDA, Md., Dec. 04, 2023 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (the “Company”), a biotechnology company leading the discovery and development of the next generation of...
Alterity Therapeutics Reports Positive Efficacy Data for ATH434 in a Primate Model of Parkinson’s Disease
December 04, 2023 07:25 ET
|
ALTERITY THERAPEUTICS LIMITED
- ATH434 improved motor performance and general function – - Webcast to be held this week to discuss new data and recent clinical progress – MELBOURNE, Australia and SAN FRANCISCO, Dec. 04,...
Gain Therapeutics to Participate in AI Driven Drug Discovery Summit
November 29, 2023 08:00 ET
|
Gain Therapeutics, Inc.
BETHESDA, Md., Nov. 29, 2023 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc., (Nasdaq: GANX), a clinical-stage biotechnology company leading the discovery and development of the next generation of...